AngioWaveNet vs Tempus ECG-AF
AI Verdict
Choose AngioWaveNet if…
Choose AngioWaveNet if your primary goal is to enhance the clarity and detail of fluoroscopic angiograms during cardiac catheterization or interventional radiology procedures. This tool is ideal for cath labs and interventional suites seeking to improve real-time vessel visualization and anatomical feature identification, integrating seamlessly with existing angiography systems.
View AngioWaveNet →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your objective is to proactively identify older patients at elevated risk of developing new-onset atrial fibrillation within the next year. This AI-based algorithm is best suited for cardiology, geriatrics, or internal medicine practices looking to leverage routine 12-lead ECGs for early risk stratification and timely follow-up for AF prevention.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AngioWaveNet | Tempus ECG-AF |
|---|---|---|
| Pricing | Pricing options include annual software licensing or subscription-based access, tailored to cath lab volume and hospital needs. custom packages are available. | Contact vendor |
| Deployment | Cloud-based or on-premise/servers | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AngioWaveNetAngioWaveNet (Tool A) emphasizes vendor-agnostic compatibility with any fluoroscopic angiography system and functions as a DICOM endpoint, suggesting broad and flexible integration into existing Cath lab workflows. Tempus ECG-AF (Tool B) specifies compatibility with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems, which might imply a more constrained integration path. AngioWaveNet also states minimal training is required and it can be configured in a few hours.
Clinical Value
AngioWaveNetAngioWaveNet (Tool A) directly enhances fluoroscopic angiograms for improved vessel visualization, providing immediate and tangible benefits during cardiac catheterization procedures. Tempus ECG-AF (Tool B) offers predictive risk stratification for Atrial Fibrillation, which is valuable for proactive care, but AngioWaveNet's impact on real-time procedural quality is arguably more immediate and critical for interventional success. Both are FDA-cleared and offer significant clinical benefits in their respective domains.
Pricing & Value
Tempus ECG-AFTempus ECG-AF (Tool B) provides a clear financial value proposition with explicit CMS reimbursement available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025). While AngioWaveNet (Tool A) offers flexible pricing models like annual licensing or subscription, it lacks specific pricing or reimbursement details, making its financial value less transparent for healthcare providers.
Enterprise Readiness
AngioWaveNetAngioWaveNet (Tool A) offers both cloud-based and on-premise deployment options and is compatible with any fluoroscopic angiography system, demonstrating high flexibility for diverse enterprise IT environments. While Tempus ECG-AF (Tool B) is HIPAA compliant and provides a BAA, AngioWaveNet's vendor-agnostic approach and deployment versatility give it an edge in adapting to various existing hospital infrastructures.
Innovation
Tempus ECG-AFTempus ECG-AF (Tool B) utilizes AI for predictive analytics, identifying patients at increased risk of developing Atrial Fibrillation within 12 months from standard ECGs, which represents a significant advancement in proactive disease management. AngioWaveNet (Tool A) innovates by enhancing existing imaging data for improved visualization during procedures, but predictive risk assessment is generally considered a more transformative application of AI in healthcare.
Support & Docs
Tempus ECG-AFTempus ECG-AF (Tool B) explicitly provides contact information for its Cardiology Support team ([email protected] or 800.739.4137) for technical support or inquiries. AngioWaveNet (Tool A) mentions full onboarding support, including installation assistance, staff training, and access to ongoing updates and clinical resources, but does not provide specific contact details for ongoing technical support.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AngioWaveNet | Tempus ECG-AF |
|---|---|---|
| Name | AngioWaveNet | Tempus ECG-AF |
| Primary Function | Enhances fluoroscopic angiograms for improved vessel visualization in cardiac catheterization laboratories. | Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. |
| Input Modality | Fluoroscopic angiograms | 12-lead ECG recordings |
| Target Use Case/Population | Improved vessel visualization in cardiac catheterization laboratories. | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, for identifying increased risk of AF within 12 months. |
| Vendor Compatibility | Compatible with any fluoroscopic angiography system (vendor-agnostic) | Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems |
| Core AI Technology | AI-powered Spatiotemporal Enhancement Processing (STEPu2122); Post-processing AI for angiographic images. | AI-based algorithm for 12-lead ECG analysis, trained on over 1.5 million ECGs. |
Videos
Demos, reviews, and walkthroughs featuring AngioWaveNet and Tempus ECG-AF.